Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Respiratory syncytial virus (RSV) is a significant respiratory pathogen affecting infants, immunocompromised children, and increasingly, the elderly.
• RSV infection in the elderly leads to substantial morbidity and mortality.
• Existing knowledge indicates widespread prior exposure to RSV across the general population, resulting in seropositivity.

Purpose of the Study:

• To assess the efficacy of a novel recombinant RSV vaccine, BBG2Na, in enhancing anti-RSV protection in RSV-primed mice.
• To characterize the immune responses induced by BBG2Na in a seropositive animal model.
• To evaluate the potential of BBG2Na for use in seropositive human populations.

Main Methods:

• Generation of a recombinant RSV vaccine, BBG2Na.
• Immunization of RSV-primed mice with BBG2Na.
• Measurement of anti-RSV-A serum antibody titers, including IgG1 and IgG2a subclasses.
• Assessment of anti-G2Na antibody levels.
• Passive transfer of sera from immunized mice to naive mice to evaluate protective efficacy.

Main Results:

• BBG2Na immunization significantly increased anti-RSV-A serum antibody titers in RSV-primed mice, indicating a mixed T-helper cell response.
• Higher levels of anti-G2Na antibodies were observed in seropositive mice immunized with BBG2Na.
• Sera from BBG2Na-immunized, RSV-primed mice conferred greater protection against RSV challenge when transferred to naive mice compared to sera from mice immunized with RSV-A only.

Conclusions:

• The BBG2Na vaccine is immunogenic and effectively boosts protective serum antibody responses in RSV-primed individuals.
• The findings support the potential clinical application of BBG2Na in seropositive human populations, including adults and the elderly.
• BBG2Na represents a promising candidate for RSV vaccination strategies targeting diverse age groups.